Scholars@Duke publication: Potency of CD8+T-cell mediated antitumor immunity from intratumoral immunotherapy with STING agonist, ADU-S100, in an esophageal adenocarcinoma model

Potency of CD8+T-cell mediated antitumor immunity from intratumoral immunotherapy with STING agonist, ADU-S100, in an esophageal adenocarcinoma model

Publication , Conference

Babar, L; Zaidi, AH; Kelly, RJ; Omstead, AN; Zheng, P; Kosovec, JE; Ayazi, S; Finley, GG; Jobe, BA; Goel, A; Gorbunova, A; Salvitti, M

Published in: JOURNAL OF CLINICAL ONCOLOGY

2020

JOURNAL OF CLINICAL ONCOLOGY

1527-7755

0732-183X

2020

APA

Chicago

ICMJE

MLA

NLM

Babar, L., Zaidi, A. H., Kelly, R. J., Omstead, A. N., Zheng, P., Kosovec, J. E., … Salvitti, M. (2020). Potency of CD8+T-cell mediated antitumor immunity from intratumoral immunotherapy with STING agonist, ADU-S100, in an esophageal adenocarcinoma model. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 38).

Babar, Laila, Ali Hussainy Zaidi, Ronan Joseph Kelly, Ashten N. Omstead, Ping Zheng, Juliann E. Kosovec, Shahin Ayazi, et al. “Potency of CD8+T-cell mediated antitumor immunity from intratumoral immunotherapy with STING agonist, ADU-S100, in an esophageal adenocarcinoma model.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 38, 2020.

Babar L, Zaidi AH, Kelly RJ, Omstead AN, Zheng P, Kosovec JE, Ayazi S, Finley GG, Jobe BA, Goel A, Gorbunova A, Salvitti M. Potency of CD8+T-cell mediated antitumor immunity from intratumoral immunotherapy with STING agonist, ADU-S100, in an esophageal adenocarcinoma model. JOURNAL OF CLINICAL ONCOLOGY. 2020.

JOURNAL OF CLINICAL ONCOLOGY

1527-7755

0732-183X

2020